Real World Experience with Tofacitinib in IBD at a Tertiary Center

BACKGROUND AND AIMS: Many inflammatory bowel disease (IBD) patients do not respond to medical therapy. Tofacitinib is a first in class, partially selective inhibitor of Janus kinase, recently approved for treating patients with ulcerative colitis (UC). We describe our experience with the use of tofa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Dig Dis Sci
Main Authors: Weisshof, Roni, Golan, Maya A., Sossenheimer, Philip H., Jurdi, Katia El, Ollech, Jacob E., Pekow, Joel, Cohen, Russel D., Sakuraba, Atsushi, Dalal, Sushila, Rubin, David T.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6935176/
https://ncbi.nlm.nih.gov/pubmed/30734234
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10620-019-05492-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados